{
    "clinical_study": {
        "@rank": "88916", 
        "arm_group": [
            {
                "arm_group_label": "RGC1", 
                "arm_group_type": "Experimental", 
                "description": "RGC containing the equivalent of 50 mg resveratrol"
            }, 
            {
                "arm_group_label": "Resveratrol", 
                "arm_group_type": "Active Comparator", 
                "description": "The equivalent of 150 mg resveratrol"
            }, 
            {
                "arm_group_label": "RGC2", 
                "arm_group_type": "Experimental", 
                "description": "RGC containing the equivalent of 150 mg resveratrol"
            }
        ], 
        "brief_summary": {
            "textblock": "This study was designed to assess the pharmacokinetics of 2 doses of Red Grape Cells (RGC)\n      containing resveratrol compared with a reference. RGC will be administered as single oral\n      dose to fasting healthy volunteers. Plasma concentration of free resveratrol and total\n      conjugates will be analyzed."
        }, 
        "brief_title": "Pharmacokinetics of Resveratrol Comprising Products", 
        "completion_date": {
            "#text": "March 2013", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Ages 18-55 years;\n\n          -  BMI >/= 19 and </= 30\n\n          -  non smoking\n\n          -  without history or evidence of significant cardiovascular, hepatic, renal,\n             respiratory, gastrointestinal disease\n\n          -  normal physical and laboratory examinations\n\n        Exclusion Criteria:\n\n          -  History or evidence of alcohol or drug abuse\n\n          -  subjects receiving chronic medication\n\n          -  unusual dietary habits or a recent change in body weight\n\n          -  acute medical situation 48 hours prior to initiation of the study\n\n          -  poor venous access\n\n          -  Subjects participated in a trial or donated blood within 4 weeks before initiation of\n             the study"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "15", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "December 9, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01747252", 
            "org_study_id": "08/12"
        }, 
        "intervention": [
            {
                "arm_group_label": "RGC1", 
                "intervention_name": "RGC", 
                "intervention_type": "Dietary Supplement"
            }, 
            {
                "arm_group_label": "RGC2", 
                "intervention_name": "RGC", 
                "intervention_type": "Dietary Supplement"
            }, 
            {
                "arm_group_label": "Resveratrol", 
                "description": "The equivalent of 150 mg resveratrol", 
                "intervention_name": "Resveratrol", 
                "intervention_type": "Dietary Supplement", 
                "other_name": "Transmax (Biotivia Ltd.)"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Resveratrol"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 1, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Beer-Sheva", 
                    "country": "Israel", 
                    "zip": "84101"
                }, 
                "name": "BioStudies Center"
            }
        }, 
        "location_countries": {
            "country": "Israel"
        }, 
        "number_of_arms": "3", 
        "official_title": "Randomized Three-way Cross-over Comparative Pharmacokinetic Study of Resveratrol Comprising Products in Fasting Healthy Subjects", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Israel: Ministry of Health", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "October 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Pharmacokinetic data such as the peak plasma concentration (Cmax), time to peak (Tmax) ans area under the concentration-time curves (AUCt) will be reported.", 
            "measure": "Individual plasma concentrations of free and conjugated resveratrol", 
            "safety_issue": "No", 
            "time_frame": "24 hours"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01747252"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Fruitura Bioscience Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Fruitura Bioscience Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}